Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTA4H | P09960 | 16/20 | 0.47 |
| ▸ | KCNH2 | Q12809 | 8/20 | 0.47 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.45 |
| ▸ | ACKR3 | P25106 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | PPARG | P37231 | 2/20 | 0.40 |
| ▸ | PPARA | Q07869 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4693581 | 0.95 | LTA4H (0.48) | LTA4HKCNH2EPHX2CYP1A2CYP3A4 | |
| SCHEMBL4711037 | 0.87 | LTA4H (0.48) | LTA4HKCNH2EPHX2ACKR3CYP1A2 | |
| SCHEMBL4689321 | 0.87 | LTA4H (0.48) | LTA4HKCNH2EPHX2ACKR3CYP1A2 | |
| SCHEMBL4689460 | 0.85 | LTA4H (0.47) | LTA4HKCNH2EPHX2ACKR3CYP1A2 | |
| SCHEMBL4711521 | 0.85 | LTA4H (0.42) | LTA4HKCNH2EPHX2ACKR3CYP1A2 | |
| SCHEMBL2168481 | 0.81 | LTA4H (0.56) | LTA4HKCNH2EPHX2CYP1A2CYP3A4 | |
| SCHEMBL4688888 | 0.81 | LTA4H (0.64) | LTA4HKCNH2EPHX2CYP1A2CYP3A4 | |
| SCHEMBL31687468 | 0.80 | ACKR3 (0.55) | KCNH2ACKR3CYP3A4 | |
| SCHEMBL4711638 | 0.80 | LTA4H (0.51) | LTA4HKCNH2CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL2169610 | 0.79 | LTA4H (0.50) | LTA4HKCNH2EPHX2CYP1A2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1660491-B1 | BENZIMIDAZOLE, BENZTHIAZOLE AND BENZOXAZOLE DERIVATIVES AND THEIR USE AS LTA4H MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2008-08-06 | — | — | EP | claimed |
| EP-1660491-A1 | BENZIMIDAZOLE, BENZTHIAZOLE AND BENZOXAZOLE DERIVATIVES AND THEIR USE AS LTA4H MODULATORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-05-31 | — | — | EP | claimed |
| US-20050043379-A1 | LTA4H Modulators | JANSSEN PHARMACEUTICA, N.V. (BE) | 2005-02-24 | — | — | US | claimed |
| WO-2005012296-A1 | BENZIMIDAZOLE, BENZTHIAZOLE AND BENZOXAZOLE DERIVATIVES AND THEIR USE AS LTA4H MODULATORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2005-02-10 | — | — | WO | claimed |
| EP-1660491-A1 | BENZIMIDAZOLE, BENZTHIAZOLE AND BENZOXAZOLE DERIVATIVES AND THEIR USE AS LTA4H MODULATORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-05-31 | — | — | EP | disclosed |
| WO-2005012296-A1 | BENZIMIDAZOLE, BENZTHIAZOLE AND BENZOXAZOLE DERIVATIVES AND THEIR USE AS LTA4H MODULATORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2005-02-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050043379-A1 | LTA4H Modulators | LTA4H, LTB4R, LTB4R2 | LTA4H 1/4885KCNH2 3429/4885EPHX2 101/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.